CeGaT’s next-generation sequencing facility awarded Illumina CSPro Certification

CeGaT has successfully completed Illumina CSPro™ certification for sequencing, gaining entry to an elite group of Illumina genomics service providers globally.

CeGaT is a dedicated diagnostics company and sees itself as a medical service provider. Achieving the highest possible quality in all steps of the process is of utmost importance for us. Being awarded Illumina CSPro attests to our high-quality strategy.

View more “About CeGaT“.

CeGaT receives 10,000 th sample

Today, we received the 10,000 th sample.

At the molecular genetic diagnosis, the quality of the analysis is our top priority. We were also able to reduce the processing time for diagnostic panels to less than three months.

We thank all sender for their trust.

View more “About CeGaT“.

CeGaT extended diagnostics pipeline: Third HiSeq 2500 from Illumina goes into operation

The course of CeGaT is furthermore on the rise. This makes an increase in capacity necessary and leads to an investment in a third HiSeq 2500 from Illumina. Therefore, the following NGS platforms are in use in our laboratory:

  • 3 x HiSeq 2500 (Illumina)
  • 1 x MiSeq (Illumina)
  • 1 x IonTorrent PGM (Life Technologies)

View more “About CeGaT“.

CeGaT’s Exome Sequencing identifies the cause of a rare syndrom

CeGaT successfully clarified the cause for a patient’s disease by sequencing and diagnosing the exomes of the young patient and their parents. A point mutation was found in the gene SATB2 which caused the disease. To date, only one mutation in the SATB2-gene has been identified worldwide. Together with the Klinikum Stuttgart, the phenotype of the SATB2-associated syndrome (SAS) was described and published in the European Journal of Human Genetics.

CeGaT offer most comprehensive Diagnostics of Tumors

CeGaT has developed a panel for the detection of somatic mutations in cancer. More than 550 state of the art genes relevant for cancer have been selected to create the most comprehensive NGS cancer gene panel available. Somatic mutations are detected by comparing the sequences of tumor and normal tissue. A very high coverage allows the detection of mutations even in tumor subclones or in samples with low tumor content. Knowledge of somatic mutations helps to select an individual therapy to improve the response rate and reduce side effects.

Simultaneously CeGaT has updated the hereditary cancer panels, adding new genes and new panels. Beside the panels for colon cancer, breast and ovarian cancer, prostate cancer, pheochromocytoma and tumor syndromes there are now panels for renal cell cancer, pancreatic cancer, familial melanoma and the tumor associated syndromes Xeroderma Pigmentosum and Fanconi Anemia.

Please visit the new section of our Tumor Diagnostics.